Company intelligence / Profile preview

Patara Pharma

San Diego, California, United Statesorpha.net ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Patara Pharma was a San Diego-based clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting allergic and inflammatory diseases in orphan or underserved patient populations. Its lead candidate, PA101B—a proprietary inhaled GPR35 agonist—showed positive results in a Phase IIa trial for refractory chronic cough associated with IPF. The company also explored indications such as indolent systemic mastocytosis and uremic pruritus. Following the acquisition of its main asset by Roivant/Respivant, Patara ceased operations around late 2018.

Therapeutic areas: HematologyPulmonologyImmunologyNephrology
Modalities: Small molecules (notably GPR35 agonists such as PA101B)
Industry: Biotech

Drug pipeline

1 asset

PA101B

Phase 2

Indications: Refractory chronic cough, Idiopathic pulmonary fibrosis, Indolent systemic mastocytosis

Beyond the preview

Go deeper on Patara Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Patara Pharma.

Explore the full profile